Drug Profile
GSK 2820151
Alternative Names: GSK2820151Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antineoplastics
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 08 Oct 2019 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02630251)
- 28 May 2019 No recent reports of development identified for phase-I development in Solid-tumours in USA (PO, Capsule)
- 25 Apr 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT02630251)